Management of Diabetes in Special Populations

Participants should be aware of the following financial/non-financial relationships:
Katherine R. Tuttle, MD, FASN, FACP, FNKF: AstraZeneca : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Bayer : Honorarium (Status: Ongoing); Boehringer Ingelheim : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Eli Lilly : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Gilead : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Goldfinch Bio : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Grant/Research Support (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing); Novo Nordisk : Consulting Fees (e.g., advisory boards) (Status: Ongoing)